Safety and feasibility of intensive endoscopic interventions for delayed perforation after colorectal endoscopic submucosal dissection (with video)
- PMID: 40210010
- DOI: 10.1016/j.gie.2025.03.1328
Safety and feasibility of intensive endoscopic interventions for delayed perforation after colorectal endoscopic submucosal dissection (with video)
Abstract
Background and aims: Colorectal endoscopic submucosal dissection (ESD) is widely performed for large superficial colorectal tumors; however, it can lead to adverse events such as delayed perforation, which may require emergency surgery. Our goal was to elucidate the clinical course of delayed perforation and the safety and feasibility of intensive endoscopic interventions.
Methods: Patients diagnosed with delayed perforation after colorectal ESD between February 2011 and April 2023 were retrospectively analyzed. Delayed perforation was defined as follows: no perforation during ESD; abdominal pain and fever after ESD; and extraluminal gas identified during CT imaging.
Results: ESD was performed for 1763 patients with 1845 lesions (right-sided colon, 1018; left-sided colon, 827). Thirty-three delayed perforations (27 between 2011 and 2020; 6 between 2021 and 2023) occurred. Muscle injury occurred during ESD in 4 patients. The ESD ulcer was closed in 6 patients. CT imaging was performed when abdominal pain with fever (n = 17), abdominal pain (n = 13), fever (n = 2), and fatigue (n = 1) were observed. The median period between ESD and CT imaging was 22 hours (IQR, 8-41.25 hours). Seven patients required emergency surgery between 2011 and 2020; of these patients, 5 underwent surgery within 6 hours after CT imaging and 2 required surgery after conservative treatment. Endoscopy was performed for 5 of 6 patients between 2021 and 2023. Endoscopic intervention and successful conservative treatment were performed after identification of the perforation.
Conclusions: Intensive endoscopic interventions for delayed perforation after ESD may prevent emergency surgery.
Copyright © 2025 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The following authors disclosed financial relationships: S. Shichijo: honoraria for lectures from Fujifilm, Boston Scientific Japan, EA Pharma, AstraZeneca, Daiichi-Sankyo Co, Ltd, AI Medical Service, Zeria Pharmaceutical Co, Ltd, and Janssen Pharmaceutical Co, Ltd. Y. Takeuchi: honoraria for lectures from Olympus, Fujifilm, Boston Scientific Japan, Daiichi-Sankyo, Miyarisan Pharmaceutical, EA Pharma, Zeria Pharmaceutical, Viatris, Tsumura & CO, Kyorin Pharmaceutical, Otsuka Pharmaceutical Factory, Fuji Pharma Co, AI Medical Service and Takeda Pharmaceuticals. N. Uedo: honoraria for lectures from Olympus, Fujifilm, Boston Scientific Japan, Daiichi-Sankyo, Takeda Pharmaceutical, EA Pharma, Otsuka Pharmaceutical, AstraZeneca, and Miyarisan Pharmaceutical. T. Kanesaka: honoraria for lectures from Olympus, AstraZeneca, and the AI Medical Service.
LinkOut - more resources
Full Text Sources
Miscellaneous
